ORCHARD: Osimertinib plus necitumumab in patients (pts) with advanced NSCLC whose disease progressed on first-line (1L) osimertinib

被引：3

作者：

Riess, J. W. ^{[1
]}

De Langen, J. A. ^{[2
]}

Piotrowska, Z. ^{[3
]}

Goldberg, S. B. ^{[4
]}

Goldman, J. W. ^{[5
]}

Okamoto, I. ^{[6
]}

Ponce Aix, S. ^{[7
,8
]}

Teraoka, S. ^{[9
]}

Ambrose, H. ^{[10
]}

Tang, K. H. ^{[11
]}

Maidment, J. ^{[12
]}

Ruiz, B. Merchan ^{[13
]}

Hewson, N. ^{[10
]}

Cosaert, J. ^{[13
]}

Yu, H. A. ^{[14
,15
]}

机构：

[1] UC Davis Comprehens Canc Ctr, Hematol & Oncol, Sacramento, CA USA

[2] Antoni van Leeuwenhoek Hosp, Netherlands Canc Inst, Dept Thorac Oncol, Amsterdam, Netherlands

[3] Massachusetts Gen Hosp, Dept Med, Boston, MA USA

[4] Yale Sch Med, Dept Med Med Oncol, New Haven, CT USA

[5] Univ Calif Los Angeles, Dept Med, David Geffen Sch Med, Santa Monica, CA USA

[6] Kyushu Univ, Res Inst Dis Chest, Grad Sch Med Sci, Fukuoka, Japan

[7] Hosp Univ 12 Octubre, Dept Med Oncol, Madrid, Spain

[8] Ctr Nacl Invest Oncol, Madrid, Spain

[9] Wakayama Med Univ, Internal Med 3, Wakayama, Japan

[10] AstraZeneca Oncol R&D, Early Oncol, Cambridge, England

[11] AstraZeneca, Translat Med, Oncol R&D, Boston, MA USA

[12] AstraZeneca, Oncol Patient Safety, Oncol R&D, Cambridge, England

[13] AstraZeneca Oncol R&D, Res & Early Dev, Cambridge, England

[14] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY USA

[15] Weill Cornell Med Coll, New York, NY USA

来源：

关键词：

D O I：

10.1016/j.annonc.2022.10.368

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

329P

引用

页码：S1571 / S1572

页数：2